MONDAY, Dec. 30, 2024 -- For treatment of scalp psoriasis, the efficacy and safety of tildrakizumab seen at week 16 (W16) are maintained through week 52 (W52), according to a study published online Dec. 22 in the Journal of the American Academy of Dermatology.

Howard L. Sofen, M.D., from the David Geffen School of Medicine at UCLA in Los Angeles, and colleagues examined maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis, which was demonstrated in the primary analysis of a phase 3b randomized trial at W16. Patients randomly assigned to tildrakizumab continued to receive tildrakizumab 100 mg every 12 weeks, while those randomly assigned to placebo were switched to tildrakizumab 100 mg at W16 (received tildrakizumab 100 mg at W16, W20, W32, and W44).

The researchers found that in patients originally randomly assigned to tildrakizumab versus placebo, the efficacy end points of Investigator Global Assessment modified 2011 (scalp) score of 0 or 1 with improvement of two grades or greater rose from 49.4 versus 7.3 percent at W16 to 62.9 versus 56.1 percent at W52. Furthermore, a ≥90 percent improvement in the Psoriasis Scalp Severity Index score from baseline improved from 60.7 versus 4.9 percent at W16 to 65.2 versus 57.3 percent at W52. Response was maintained by more than 80 percent of W16 responders to tildrakizumab. There were no treatment-related serious adverse events reported.

"The results in the present study demonstrate the efficacy and safety of tildrakizumab for the treatment of scalp psoriasis are maintained for up to 52 weeks of treatment in a clinical trial setting," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Sun Pharma, which manufactures tildrakizumab and funded the study.